Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer

Chemotherapies that target thymidylate synthase (TS) continue to see considerable clinical expansion in non–small cell lung cancer (NSCLC). One drawback to TS-targeted therapies is drug resistance and subsequent treatment failure. Novel therapeutic and biomarker-driven strategies are urgently needed. The enzyme deoxyuridine triphosphate nucleotidohydrolase (dUTPase) is reported to protect tumor cells from aberrant misincorporation of uracil during TS inhibition. The goal of this study was to investigate the expression and significance of dUTPase in mediating response to TS-targeted agents in NSCLC. The expression of dUTPase in NSCLC cell lines and clinical specimens was measured by quantitative real-time reverse transcriptase PCR and immunohistochemistry. Using a validated RNA interference approach, dUTPase was effectively silenced in a panel of NSCLC cell lines and response to the fluoropyrimidine fluorodeoxyuridine (FUdR) and the antifolate pemetrexed was analyzed using growth inhibition and clonogenic assays. Apoptosis was analyzed by flow cytometry. Significant variation in the quantity and cellular expression of dUTPase was observed, including clear evidence of overexpression in NSCLC cell line models and tumor specimens at the mRNA and protein level. RNA interference–mediated silencing of dUTPase significantly sensitized NSCLC cells to growth inhibition induced by FUdR and pemetrexed. This sensitization was accompanied by a significant expansion of intracellular dUTP pools and significant decreases in NSCLC cell viability evaluated by clonogenicity and apoptotic analyses. Together, these results strongly suggest that uracil misincorporation is a potent determinant of cytotoxicity to TS inhibition in NSCLC and that inhibition of dUTPase is a mechanism-based therapeutic approach to significantly enhance the efficacy of TS-targeted chemotherapeutic agents. Mol Cancer Ther; 11(3);616–28. ©2011 AACR.

[1]  S. Carr,et al.  Characterization of Distinct Nuclear and Mitochondrial Forms of Human Deoxyuridine Triphosphate Nucleotidohydrolase (*) , 1996, The Journal of Biological Chemistry.

[2]  C. Heidelberger,et al.  Studies on fluorinated pyrimidines. IV. Effects on nucleic acid metabolism in vivo. , 1958, Cancer research.

[3]  H. Lenz,et al.  The dual EGFR/HER‐2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN‐38 , 2009, International journal of cancer.

[4]  R. Schultz,et al.  Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). , 1998, Advances in enzyme regulation.

[5]  M. Vincent.  Pemetrexed: potential role in the adjuvant chemotherapy of non-small cell lung cancer. , 2010, Current drug targets.

[6]  C. Heidelberger,et al.  Studies on fluorinated pyrimidines. V. Effects on nucleic acid metabolism in vitro. , 1958, Cancer research.

[7]  S. Caradonna,et al.  Inhibition of phosphorylation of cellular dUTP nucleotidohydrolase as a consequence of herpes simplex virus infection , 1990, Journal of cellular biochemistry.

[8]  N. Neamati,et al.  Novel opportunities for thymidylate metabolism as a therapeutic target , 2008, Molecular Cancer Therapeutics.

[9]  R. Ladner,et al.  Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition. , 2004, Molecular pharmacology.

[10]  H. Lenz,et al.  Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells , 2009, International journal of cancer.

[11]  G. Scagliotti,et al.  Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase , 2006, Cancer.

[12]  K. Nishio,et al.  Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer , 2011, British Journal of Cancer.

[13]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[14]  C. Heidelberger,et al.  Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. , 1958, Cancer research.

[15]  G. Aherne,et al.  The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition , 2001, British Journal of Cancer.

[16]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[17]  I. Okamoto,et al.  Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. , 2011, Lung cancer.

[18]  H. Ingraham,et al.  Mechanism of thymineless death. , 1986, Advances in experimental medicine and biology.

[19]  R. Ladner,et al.  Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitorD9331 , 2000, British Journal of Cancer.

[20]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[21]  G. Peters,et al.  Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. , 2003, Biochemical pharmacology.

[22]  R. Ladner,et al.  dUTPase and uracil-DNA glycosylase are central modulators of antifolate toxicity in Saccharomyces cerevisiae. , 2002, Cancer research.

[23]  J. Holland,et al.  Experiments with some mouse tumors and leukemias. , 1958, Cancer research.

[24]  M. Fukushima,et al.  Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT , 2006, British Journal of Cancer.

[25]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Goldman,et al.  Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications , 2007, Molecular Cancer Therapeutics.

[27]  E. Brambilla,et al.  The evolving role of histology in the management of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Y. Hu,et al.  [Thymidylate synthase expression and therapeutic effect analysis of pemetrexed in advanced lung adenocarcinoma]. , 2010, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[29]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[30]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[31]  S. Monfardini,et al.  Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. , 2002, Cancer treatment reviews.

[32]  I. Judson,et al.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. , 1991, Cancer research.

[33]  R. Pazdur,et al.  Thymidylate synthase inhibitors. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  S. Groshen,et al.  A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy , 2010, Cancer Chemotherapy and Pharmacology.

[35]  C. Heidelberger,et al.  Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds , 1957, Nature.

[36]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Houghton,et al.  Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. , 1994, Cancer research.

[38]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[39]  S. Tucker.  The role of pemetrexed in second-line chemotherapy for advanced non-small cell lung cancer. , 2010, Current drug targets.

[40]  P. Wilson,et al.  A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates , 2011, Nucleic acids research.

[41]  H. Ingraham,et al.  DNA fragmentation and cytotoxicity from increased cellular deoxyuridylate. , 1986, Biochemistry.

[42]  Elisa Giovannetti,et al.  Thymidylate synthase inhibitors for non-small cell lung cancer , 2011, Expert opinion on investigational drugs.

[43]  Wancai Yang,et al.  Genetic Determinants of Pemetrexed Responsiveness and Nonresponsiveness in Non-small Cell Lung Cancer Cells , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[44]  G. Scagliotti,et al.  Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  D. Santi,et al.  The catalytic mechanism and structure of thymidylate synthase. , 1995, Annual review of biochemistry.

[47]  A. Matakidou,et al.  Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  H. Blomgren,et al.  Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Ueda,et al.  Significance of thymidylate synthase for resistance to pemetrexed in lung cancer , 2010, Cancer science.

[50]  Cancer Facts & Figures 2021 , 2010 .

[51]  T. Lawrence,et al.  Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate. , 1993, Cancer research.

[52]  Jou-Wei Lin,et al.  Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. , 2011, Lung cancer.

[53]  D. Gandara,et al.  Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy. , 2010 .

[54]  N. Tanner,et al.  Lung cancer: Progress in diagnosis, staging and therapy , 2010, Respirology.

[55]  T. Lawrence,et al.  Induction of resistance to fluorodeoxyuridine cytotoxicity and DNA damage in human tumor cells by expression of Escherichia coli deoxyuridinetriphosphatase. , 1994, Cancer research.